Testing effectiveness (Phase 2)Study completedNCT01282463
What this trial is testing
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Who this might be right for
Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more
Eli Lilly and Company 148